Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients

Lignende værker

• Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
  af: Hong, Woo Sung, et al.
  Udgivet: (2013)
• Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial
  af: Swain, Sandra M., et al.
  Udgivet: (2008)
• Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents
  af: Abdel-Razeq, Hikmat, et al.
  Udgivet: (2020)
• Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study
  af: Batra, Atul, et al.
  Udgivet: (2020)
• Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
  af: Xu, Qiaoping, et al.
  Udgivet: (2021)